Condition specific antepartum testing: systemic lupus erythematosus and associated serologic abnormalities.
Antepartum fetal surveillance is well established in the optimal management of any pregnancy complicated by maternal systemic lupus erythematosus and/or its associated serologic abnormalities. Our experience in antepartum surveillance of the "lupus pregnancy" from 1980 to 1988 is reviewed. An overall perinatal mortality rate of 6.06% compares favorably to the total intrauterine death rate range usually reported for this disease.
Adams
D
D
Department of Obstetrics and Gynecology, New York Hospital-Cornell Medical Center, New York 10021.
Druzin
M L
ML
Edersheim
T
T
Bond
A
A
Kogut
E
E
D017153:Antibodies, Anticardiolipin / Q000032:analysis*; D001241:Aspirin / Q000627:therapeutic use; D001327:Autoimmune Diseases / Q000097:blood* / Q000276:immunology; D005260:Female; D005313:Fetal Death / Q000453:epidemiology / Q000209:etiology* / Q000517:prevention & control; D005317:Fetal Growth Retardation / Q000209:etiology; D005323:Fetal Monitoring; D006801:Humans; D007231:Infant, Newborn; D016682:Lupus Coagulation Inhibitor / Q000032:analysis*; D008180:Lupus Erythematosus, Systemic / Q000097:blood* / Q000276:immunology; D015166:Monitoring, Immunologic; D011247:Pregnancy; D011248:Pregnancy Complications / Q000097:blood* / Q000276:immunology; D011256:Pregnancy Outcome; D012680:Sensitivity and Specificity
D017153:Antibodies, Anticardiolipin; D016682:Lupus Coagulation Inhibitor; D001241:Aspirin